Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.

ABSTRACT:

Background

Interleukin 22 promotes epidermal hyperplasia and inhibits skin barrier function.

Objective

Evaluate interleukin 22 blockade in adults with moderate-to-severe atopic dermatitis (AD).

Methods

We performed a randomized, double-blind, placebo-controlled trial with intravenous fezakinumab monotherapy every 2 weeks for 10 weeks, with follow-up assessments until 20 weeks. The change in SCOring AD (SCORAD) score from baseline at 12 weeks served as the primary end point.

Results

At 12 weeks, the mean declines in SCORAD for the entire study population were 13.8 ± 2.7 in the fezakinumab arm and 8.0 ± 3.1 in the placebo arm (P = .134). In the severe AD patient subset (with a baseline SCORAD of ≥50), SCORAD decline was significantly stronger in the drug-treated

SUBMITTER: Guttman-Yassky E 

PROVIDER: S-EPMC8711034 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature